Navigation Links
Scientists develop 'cyborg engineering' for coronary bypass grafting
Date:6/3/2008

A team of London scientists have taken a major step in making the use of artificial veins and arteries in coronary bypass grafts a reality. In a study published in the June 2008 print issue of The FASEB Journal (http://www.fasebj.org), researchers describe how they developed this artificial graft tissue by combining man-made materials with human cells to make it elastic and durable and so it can attach to host tissue.

"Obviously this advance could be a medical breakthrough that saves millions of lives around the world," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal, "but even more tantalizing is the successful fusing of living cells to nonliving substances that actuallyhealby forming a stronger bond to each other and to host tissue once put in use. This might even be called a start toward 'cyborg engineering.'"

In the research report, scientists describe how they took an elastic scaffold (the material that gives the artificial graft its shape) of compliant poly(carbonate-urea)urethane and incorporated human vascular smooth muscle cells and epithelial cells from umbilical cords. Then they took the artificial grafts and simulated blood flow in the laboratory to test their durability. They found that as the pulsing fluid flow slowly increased, the artificial graft's performance actually improved. The researchers hypothesize that this improvement is because the movement of fluid through the graft stimulates the smooth muscle and epithelial cells to release proteins that strengthen their ability to attachment to the elastic scaffold and other tissues.

"The notion that any body part could be engineered in a lab, attach to existing tissue 'naturally,' and grow stronger as it is being used is something thought completely impossible just 20 years ago," Weissmann added. "It is only a matter of time before human tissues can be engineered to be at least as good as the originals, and this study moves us toward that reality."

According to the National Institutes of Health, coronary artery bypass grafting is the most common open heart surgery in the United States, with 500,000 procedures performed each year. It is one of only a few surgical options to treat coronary artery disease, which is the leading cause of death in the United States. During this surgery, a healthy vein or artery from another part of the body is connected to the blocked coronary artery to route blood flow around a blocked passage. Current procedures are limited, however, by the availability of healthy veins or arteries as well as the patient's ability to survive both aspects of the procedure. Furthermore, many patients experience significant pain in the area where the vein or artery was removed. Using artificial veins or arteries instead would reduce recovery time, reduce pain, and save lives by making this type of surgery more available to people who need it.


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage ... up its marketing efforts with its product now available through Jet.com. , After ... public. The effervescent powdered drink is designed to quickly detox the body thereby avoiding ...
(Date:8/18/2017)... ... 2017 , ... 800response, the leading provider of dynamic call-to-action ... launch of a redesigned corporate website, 800response.com . , Key features ... an enhanced search directory for businesses and advertising agencies to use to ...
(Date:8/18/2017)... ... ... “Dangerous Inheritance”: a mystery about saving the family farm. “Dangerous Inheritance” ... where she was raised on a farm. As Diane wrote this story, she ... friendships and mantra of ‘neighbors helping neighbors’ have always been a large part of ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Beyond Our Imaginations: The Infinite God”: shows the ... Infinite God” is the creation of published author, Mark Lawrence, born in Michigan, the ... “The problem with becoming a greater man of God is that I have to ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... International plc (NASDAQ: ENDP ) today announced that ... U.S. mesh product liability claims and that it is ... claims at reasonable values. Under the agreements, Endo will ... 2017 and continuing through the fourth quarter of 2019. ... Company intends to increase its mesh product liability accrual ...
(Date:8/2/2017)... 2, 2017 Fenita J. Caldwell ... a Pinnacle Lifetime Professional in the Field of ... at Turing Pharmaceuticals, AG. Her skills and areas ... building.                ... years of experience as a highly successful sales ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
Breaking Medicine Technology: